Darolutamide - Bayer HealthCare/ Orion

Drug Profile

Darolutamide - Bayer HealthCare/ Orion

Alternative Names: BAY 1841788; ODM 201

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orion
  • Developer Bayer HealthCare; European Organisation for Research and Treatment of Cancer; Institute Gustave-Roussy; Orion; Swiss Group for Clinical Cancer Research
  • Class Amides; Antiandrogens; Antineoplastics; Pyrazoles; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 05 Apr 2018 Updated preclinical pharmacodynamics data in Prostate cancer released by Bayer
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, In the elderly, Metastatic disease, In adults) in Japan (PO, Capsule)
  • 18 Jan 2018 Bayer completes a phase I trial for Prostate cancer (Metastatic disease, Hormone-refractory, In adults, In the elderly) in Japan (PO) (NCT02363855)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top